General points
• The evidence available for the use of antidepressants drug therapy to treat comorbid depression in patients with COPD is inconclusive [53, 54]. In the absence of clear evidence of benefits, it is important for clinicians to monitor COPD patients using a validated depression rating scale regularly and following any patient who has been prescribed antidepressants to determine response to therapy and the emergence of the prescription of antidepressants for any adverse events.
• When prescribing antidepressants, the principle of ‘start low and go slow’ should be followed provided there is an attempt to but try not reach a therapeutic dose in patients with adequate tolerance.
• Prior to commencing antidepressant drug treatment, COPD patients should be informed of potential side effects. It is important to emphasise that most of side effects are transient and to ensure that clinician backup is easily available make yourself available in case side effects develop.
Specific medication points
• Depressed COPD patients who are poorly tolerating or failing to respond antidepressants should be referred to a psychiatrist for detailed assessment.
• In older people, it has been reported over the third of the patients [49] on SSRIs and tramadol or oxycodone exhibit drug interactions. Thus, older patients who are treated with combined drugs require close monitoring and adjust the therapeutic doses accordingly in relation to patients’ symptoms in order to reduce potential side effects. Opioids in lower doses (<30 mg oral morphine equivalent per day) are not associated with increased hospital admission or deaths in patients receiving long-term oxygen therapy for COPD.
• Benzodiazepines and opioids in higher doses might increase mortality in patients with chronic respiratory diseases.
• Lower-dose opioids might be safe for reducing symptoms of dyspnoea in patients with respiratory disease.
Safety data from clinical practice for benzodiazepines and opioids in patients with severe COPD are lacking.
Lower doses of opioids are beneficial in ameliorating dyspnoea in patients with COPD without series adverse events. However, only a few studies have been conducted to address this question and they are all small in sample size. Thus, again, prospective randomised controlled trials with larger sample sizes are required. Additionally, the safety of benzodiazepines for use in patients with severe COPD requires further investigation.
References
1.
World Health Organization report. 2008. http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/index.html.
2.
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, Mahler DA, Meek PM, O’Donnell DE; on behalf of the ATS Committee on Dyspnea. 2012. An official American thoracic society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–52.
3.
4.
5.
6.
Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55(12):1000–6.CrossRefPubMedPubMedCentral
7.
8.
Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(3):280–8.
9.
10.
Yohannes AM. Palliative care and management principles in older patients with advanced chronic obstructive pulmonary disease. J Ageing Health. 2011;7(3):409–21.CrossRef
11.
12.
Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA. ACCP workshop panel on anxiety and depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(Suppl 4):43S–56S.CrossRefPubMedPubMedCentral
13.
NICE guideline. Depression in adults: The treatment and management of depression in adults. 2009. www.nice.org.uk/CG090. Accessed 13 June 2014.
14.
Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. Drugs Aging. 2014;31:483–92.CrossRefPubMedPubMedCentral
![](https://freepngimg.com/download/social_media/63059-media-icons-telegram-twitter-blog-computer-social.png)
Stay updated, free articles. Join our Telegram channel
![](https://clinicalpub.com/wp-content/uploads/2023/09/256.png)
Full access? Get Clinical Tree
![](https://videdental.com/wp-content/uploads/2023/09/appstore.png)
![](https://videdental.com/wp-content/uploads/2023/09/google-play.png)